Obamacare: The Politics of Health Care Reform Entering the Endgame
This article was originally published in RPM Report
Executive Summary
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.
You may also be interested in...
Quality Leadership: The Challenge and Opportunity Facing CMS Nominee Berwick
Institute for Healthcare Improvement CEO Don Berwick is the pick to run CMS during the health care reform implementation period. If confirmed, he will have a golden opportunity to try out quality improvement ideas on a national stage.
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.
Bending The Cost Curve: Harvard's Cutler Says Rx Can Play A Big Role
Health care cost trends may not be so bad after all, former Obama advisor writes in New England Journal of Medicine. Prescription drugs can help, he writes-but not entirely in the way industry would hope.